Legend Biotech Q4 EPS $(0.40) May Not Be Comparable To $(0.83) Estimate, Sales $79.46M Miss $86.35M Estimate
Portfolio Pulse from Benzinga Newsdesk
Legend Biotech (NASDAQ:LEGN) reported Q4 earnings with losses of $(0.40) per share, beating the $(0.83) estimate by 51.81%. However, their sales of $79.46M missed the $86.35M estimate by 7.97%. Year-over-year, this represents a 2.44% decrease in losses and a 187.57% increase in sales.
March 11, 2024 | 11:03 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Legend Biotech reported better-than-expected Q4 EPS but missed on sales estimates. Year-over-year, losses decreased slightly while sales significantly increased.
The mixed earnings report from Legend Biotech, with a significant beat on EPS estimates but a miss on sales forecasts, presents a neutral short-term impact. The better-than-expected EPS could be seen positively by investors, indicating operational efficiency or cost management. However, the miss on sales forecasts could raise concerns about revenue growth and market demand for its products. The significant year-over-year sales increase might mitigate some concerns, indicating long-term growth potential.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100